Combination Treatment Vastly Improves DLBCL Care
- Okay,here's a summary of the provided text,broken down into key points:
- Main Topic: A promising combination therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- * Combination: Loncastuximab tesirine-lpyl (Zynlonta - an antibody-drug conjugate or ADC) plus glofitamab-gxbm (Columvi - a bispecific antibody) is being evaluated in the LOTIS-7 trial.
Okay,here’s a summary of the provided text,broken down into key points:
Main Topic: A promising combination therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Key Findings:
* Combination: Loncastuximab tesirine-lpyl (Zynlonta – an antibody-drug conjugate or ADC) plus glofitamab-gxbm (Columvi – a bispecific antibody) is being evaluated in the LOTIS-7 trial.
* High Response rate: A 90.9% complete response rate was observed in 22 efficacy-evaluable patients.
* Improved Safety: The combination appears to have a “manageable” safety profile and may improve the safety of glofitamab when used alone. ADCs seem to enhance both efficacy and safety of bispecific antibodies.
* Potential for Earlier Use: Researchers hope to explore this combination in earlier lines of therapy.
Expert Opinion:
* Tycel Phillips, MD (City of Hope) believes this combination is a potentially valuable treatment option.
Study details:
* Trial Name: LOTIS-7
* Presented at: Society of Hematologic Oncology (SOHO) Annual Meeting (Sept 3-6, 2025, Houston)
* Funding: ADC Therapeutics funded the study.
* Disclosure: Dr. Phillips has no relevant financial disclosures.
Important Note: the initial error message at the beginning of the text suggests a technical issue with the Healio website. It provides a customer service email address if the user continues to experience problems.